LUNA Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for LUNA from our risk checks.
My Notes
Capture your thoughts, links and company narrative
H. Lundbeck A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 4.45 |
| 52 Week High | DKK 5.57 |
| 52 Week Low | DKK 3.72 |
| Beta | 0.19 |
| 1 Month Change | -5.73% |
| 3 Month Change | -16.13% |
| 1 Year Change | 14.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| LUNA | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -4.0% | -1.0% | -1.1% |
| 1Y | 14.9% | 5.7% | -1.6% |
Return vs Industry: LUNA exceeded the Austrian Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: LUNA exceeded the Austrian Market which returned -1.6% over the past year.
Price Volatility
| LUNA volatility | |
|---|---|
| LUNA Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 2.1% |
Stable Share Price: LUNA has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: LUNA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 5,500 | Charl van Zyl | www.lundbeck.com |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.
H. Lundbeck A/S Fundamentals Summary
| LUNA fundamental statistics | |
|---|---|
| Market cap | €5.26b |
| Earnings (TTM) | €360.17m |
| Revenue (TTM) | €2.87b |
15.2x
P/E Ratio1.9x
P/S RatioIs LUNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUNA income statement (TTM) | |
|---|---|
| Revenue | DKK 21.44b |
| Cost of Revenue | DKK 4.38b |
| Gross Profit | DKK 17.06b |
| Other Expenses | DKK 14.37b |
| Earnings | DKK 2.69b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 2.71 |
| Gross Margin | 79.56% |
| Net Profit Margin | 12.53% |
| Debt/Equity Ratio | 15.6% |
How did LUNA perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 06:25 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
H. Lundbeck A/S is covered by 39 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Charles Pitman | Barclays |